Values as of: 2025-04-02
COMMON STOCK | Asset Management |
Last Closing
USD 47.62Change
0.00 (0.00)%Market Cap
USD 49.04BVolume
181.00Analyst Target
N/AVerdict
Verdict
3i Group plc is a private equity firm specializing in mature companies, growth capital, middle markets, infrastructure, and management leveraged buyouts and buy-ins. The firm also provides infrastructure financing and debt management. For debt management, it invests in senior and mezzanine corporate debt in typically large and private companies in United Kingdom, Europe, Asia, and North America. It makes private equity investments in business and technology services, financial services, consumer and private label, software and service, healthcare, consumption and distribution, media and telecom, renewable energy, wind, and industrial technology sector. Within business and technology services, the firm seeks to invest in sub sectors such as testing, inspection and certification; intelligent outsourcing, BPO and consultancy; human capital including staffing, governance, risk and compliance, services to pharmaceutical companies, vertical application software, education and training businesses; facilities management; support services to industrial sectors such as oil and gas and utilities; human resources outsourcing and advising; recruitment; logistics and infrastructure support services including distribution, waste, and rental. In the consumer sector, it focuses on, multi-unit roll out, omni-channel propositions, niche branded consumer goods, polarization, health and wellness, ageing population, millennials, consumer goods; e-commerce; retail; food and drinks; private label CMO and leisure. In the healthcare sector, the firm focuses on outsourced medical device manufacturing & services, outsourced pharmaceutical manufacturing & services, bioprocessing supply chain, life science tools and diagnostics, wellness & consumer health products, personalized medicine, pharmaceuticals and biotechnology including specialty pharma, generics or OTC, drug delivery, and animal health; healthcare services including activities such as elderly and specialty care, including caring for people in their own homes, in hospital and in co
Company Website : https://www.3i.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| PGPHF | Partners Group |
N/A |
USD 39.81B |
| EQBBF | EQT AB (publ) |
N/A |
USD 34.86B |
| LGGNY | Legal & General Group Plc |
-0.04 (-0.25%) |
USD 18.22B |
| LGGNF | Legal & General Group Plc |
+0.06 (+1.88%) |
USD 18.02B |
| AMDUF | Amundi SA |
N/A |
USD 15.55B |
| CHYYY | CHYYY |
N/A |
USD 15.54B |
| GBLBF | Groep Brussel Lambert NV |
+0.25 (+0.32%) |
USD 9.05B |
| SFNXF | Sofina Société Anonyme |
N/A |
USD 8.24B |
| ICGUF | Intermediate Capital Group PLC |
N/A |
USD 7.89B |
| IGIFF | IGM Financial Inc. |
+0.18 (+0.58%) |
USD 7.49B |
N/A
| Market Performance vs. Industry/Classification (Asset Management) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 8.18% | 76% | C+ | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 8.18% | 77% | C+ | 62% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 33.63% | 83% | B | 81% | B- | ||
| Dividend Return | 1.22% | 8% | B- | 13% | F | ||
| Total Return | 34.86% | 83% | B | 79% | B- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 438.69% | 99% | N/A | 95% | A | ||
| Dividend Return | 31.35% | 47% | F | 63% | D | ||
| Total Return | 470.04% | 99% | N/A | 93% | A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 40.60% | 80% | B- | 76% | C+ | ||
| Dividend Return | 43.88% | 81% | B- | 75% | C | ||
| Total Return | 3.28% | 50% | F | 59% | D- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 38.07% | 57% | F | 61% | D- | ||
| Risk Adjusted Return | 115.28% | 99% | N/A | 99% | N/A | ||
| Market Capitalization | 49.04B | 100% | F | 98% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
